Could a cholesterol drug prevent first heart attacks in High-Risk patients?

NCT ID NCT07615179

Completed Knowledge-focused Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study observed over 4,500 adults with atherosclerotic cardiovascular disease who had never had a heart attack or stroke. Researchers compared those taking alirocumab (a cholesterol-lowering drug) to those not on similar therapy, using real-world data to see if the drug reduced the risk of heart attack, stroke, or death. Because it's observational, it can suggest but not prove whether alirocumab helps prevent these first-time events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alirocumab
What this could lead to: If this study shows alirocumab reduces heart attacks and strokes, it could support using this drug more broadly in people with artery disease who haven't yet had a major event.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It cannot prove cause and effect, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITHOUT PRIOR ISCHEMIC EVENTS

Contacts and locations

Locations

Sanofi

Bridgewater, New Jersey, 08807, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.